FeigPUHirszelPGalenMA: Hemodialysis in the treatment of life-threatening hyperphosphatemia. Clin Exp Dialysis Apheresis6: 105–111,1982
2.
BetroMG: Hypophosphataemia and hyperphosphataemia in a hospital population. Br Med J1: 273–276,1972
3.
ShieldsHM: Rapid fall of serum phosphorus secondary to antacid therapy. Gastroenterology75: 1137–1141,1978
4.
JohnsonWJO'BrienPC: Effectiveness of intestinal phosphate binders in patients maintained by hemodialysis. Nephron21: 123–130,1978
5.
TakamotoSOnishiTMorimotoS: Serum phosphate, parathyroid hormone and vitamin D metabolites in patients with chronic renal failure: Effect of aluminum hydroxide administration. Nephron40: 286–291,1985
6.
LotzMZismanEBartterFC: Evidence for a phosphorus-depletion syndrome in man. N Engl J Med278(8): 409–415,1968
7.
BerkelhammerCBearRA: A clinical approach to common electrolyte problems: 3. Hypophosphatemia. Can Med Assoc J130: 17–23,1984
8.
LeungACTHenersonISHallsDJ: Aluminum hydroxide versus sucralfate as a phosphate binder in uraemia. Br Med J286: 1379–1381,1983
9.
O'DonovanRBaldwinDHammerM: Substitution of aluminum salts by magnesium salts in control of dialysis hyperphosphataemia. LancetI: 880–882,1986
10.
SlatopolskyEWeertsCLopez-HilkerS: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med315(3): 157–161,1986
